Last reviewed · How we verify
Abciximab; reteplase; abciximab placebo; abciximab
Abciximab; reteplase; abciximab placebo; abciximab is a Glycoprotein IIb/IIIa inhibitor Small molecule drug developed by Centocor, Inc.. It is currently in Phase 3 development for Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction), Percutaneous coronary intervention (PCI) in patients at high risk for ischemic complications.
Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.
Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation. Used for Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction), Percutaneous coronary intervention (PCI) in patients at high risk for ischemic complications.
At a glance
| Generic name | Abciximab; reteplase; abciximab placebo; abciximab |
|---|---|
| Sponsor | Centocor, Inc. |
| Drug class | Glycoprotein IIb/IIIa inhibitor |
| Target | Glycoprotein IIb/IIIa integrin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Abciximab binds irreversibly to the glycoprotein IIb/IIIa integrin receptor on platelets, which is the final common pathway for platelet aggregation. By blocking this receptor, abciximab prevents fibrinogen and von Willebrand factor from cross-linking platelets, thereby inhibiting platelet clumping. This mechanism is particularly effective in acute coronary syndromes and during percutaneous coronary intervention (PCI) to reduce thrombotic complications.
Approved indications
- Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction)
- Percutaneous coronary intervention (PCI) in patients at high risk for ischemic complications
Common side effects
- Bleeding
- Thrombocytopenia
- Back pain
- Nausea
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abciximab; reteplase; abciximab placebo; abciximab CI brief — competitive landscape report
- Abciximab; reteplase; abciximab placebo; abciximab updates RSS · CI watch RSS
- Centocor, Inc. portfolio CI
Frequently asked questions about Abciximab; reteplase; abciximab placebo; abciximab
What is Abciximab; reteplase; abciximab placebo; abciximab?
How does Abciximab; reteplase; abciximab placebo; abciximab work?
What is Abciximab; reteplase; abciximab placebo; abciximab used for?
Who makes Abciximab; reteplase; abciximab placebo; abciximab?
What drug class is Abciximab; reteplase; abciximab placebo; abciximab in?
What development phase is Abciximab; reteplase; abciximab placebo; abciximab in?
What are the side effects of Abciximab; reteplase; abciximab placebo; abciximab?
What does Abciximab; reteplase; abciximab placebo; abciximab target?
Related
- Drug class: All Glycoprotein IIb/IIIa inhibitor drugs
- Target: All drugs targeting Glycoprotein IIb/IIIa integrin receptor
- Manufacturer: Centocor, Inc. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction)
- Indication: Drugs for Percutaneous coronary intervention (PCI) in patients at high risk for ischemic complications
- Compare: Abciximab; reteplase; abciximab placebo; abciximab vs similar drugs
- Pricing: Abciximab; reteplase; abciximab placebo; abciximab cost, discount & access